// November 27, 2023
Q&A: Building a More Resilient Medicines Supply Chain
In this conversation, US Pharmacopeia (USP) Director of Regulatory and Public Policy Developm
In this conversation, US Pharmacopeia (USP) Director of Regulatory and Public Policy Developm
(Disclaimer: The article below includes a discussion of key points of the guidance document.
The development of generic versions of innovator medicines is a global public health need.
With significant innovations in pharmaceuticals, including biologic drugs